We have recently revealed the structures of 34 PPARα-LBD complexed with 17 ligands, including the three fibrates [6] and the structure of PPARγ-LBD–saroglitazar (a PPARα/γ dual agonist in clinical trials for NAFLD treatment) [20]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.